• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Transplant international : >Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk – an observational, retrospective study
【24h】

Cytomegalovirus reactivation in liver transplant recipients due to hepatitis C cirrhosis is associated with higher cardiovascular risk – an observational, retrospective study

机译：由于丙型肝炎肝硬化引起的肝脏移植受者在肝脏移植受者中的缩细胞病毒反弹与较高的心血管风险有关 - 一个观测性，回顾性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary The association between cytomegalovirus ( CMV ) reactivation and cardiovascular risk has been reported in solid organ transplant populations; however, it has yet to be assessed in liver transplantation ( LT ). We aim to evaluate whether CMV reactivation is associated with cardiovascular events ( CVE ) in HCV ‐ LT patients. LT patients (2010 and 2014) due to HCV cirrhosis were included. Clinically significant CMV ( CS ‐ CMV ) was defined as viral load ( VL ) 5000?copies/ ml , need of therapy or CMV disease. Baseline variables and endpoint measures ( CVE , survival, severe recurrent hepatitis C, de novo tumors, and diabetes) were collected. One hundred and forty patients were included. At LT , a history of AHT was present in 23%, diabetes 22%, tobacco use 45%, obesity 20%, and renal impairment ( eGFR ??60?ml/min) in 26.5%. CS ‐ CMV reactivation occurred in 25% of patients. Twenty‐six patients (18.5%) developed a CVE . Cox regression analysis revealed two factors significantly associated with CVE : Pre‐ LT DM [ HR ?=?4.6 95% CI (1.6, 13), P ?=?0.004] and CS ‐ CMV [ HR ?=?4.7 95% CI (1.8, 12.5), P ?=?0.002]. CS ‐ CMV was not independently associated with the remaining endpoints except for survival ( P ?=?0.03). In our series, CS ‐ CMV reactivation was associated with a greater risk of developing CVE , thus confirming data from other solid organ transplant populations and emphasizing the need for adequate CMV control.
机译：发明内容在固体器官移植群体中据报道了细胞核病毒（CMV）再活化和心血管风险之间的关联;但是，尚未评估肝移植（LT）。我们的目标是评估CMV再激活是否与HCV-LT患者的心血管事件（CVE）相关。包括HCV肝硬化患者（2010年和2014年）。临床上显着的CMV（CS - CMV）定义为病毒载荷（VL）＆GT; 5000拷贝/ mL，需要治疗或CMV疾病。收集基线变量和终点措施（CVE，存活，严重丙型肝炎，de Novo肿瘤和糖尿病）。包括一百个患者。在LT中，AHT的历史以23％，糖尿病22％，烟草使用45％，肥胖20％和肾损伤（EGFRαα×60？ml / min）。 CS - CMV再激活发生在25％的患者中。二十六名患者（18.5％）开发了一个CVE。 COX回归分析显示与CVE显着相关的两个因素：pre-LM [HR吗？4.6 95％CI（1.6,13），P？= 0.004]和CS - CMV [HR？4.7 95％CI（ 1.8,12.5），p？= 0.002]。 CS - CMV与除存活以外的剩余端点没有独立相关（P？= 0.03）。在我们的系列中，CS - CMV再激活与开发CVE的风险更大，从而确认来自其他固体器官移植群体的数据，并强调需要足够的CMV控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号